GoodRx Holdings, Inc. Q2 2026 Earnings Recap

Shares rallied 12.5% following GoodRx’s Q2 report, driven by better-than-expected revenue growth—most notably a 76% year-over-year surge in Pharma Direct revenue—and an upgraded full-year outlook reflecting increased confidence in returning to year-over-year growth sooner than anticipated.

Key Takeaways

• Pharma Direct revenue accelerated 76% year-over-year and 18% quarter-over-quarter, led by expanded consumer direct pricing programs including major brands like Jardiance and Otezla.
• GLP-1 medication demand remains robust, with GoodRx supporting several new launches, solidifying its role as a key consumer access channel in this high-growth segment.
• Subscription initiatives, including the recent launch of GoodRx Companion, are becoming increasingly central to customer retention and engagement strategies.
• Management raised full-year revenue and adjusted EBITDA guidance based on strong Q2 trends, signaling confidence in sustaining growth momentum.
• Leadership change: previously Chief Strategy and Operations Officer Justin Fengler appointed CFO, ensuring continuity in financial leadership amid the company’s strategic evolution.